CTRI/2022/12/047807招募中3 期
A Double-blind double dummy prospective randomized study to evaluate the efficacy of classical Ayurveda management versus Methotrexate in Rheumatoid Arthritis (AMRA Study). - AMRA
Central Council for Research in Ayurvedic Science CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Adult male or female aged between 18 and 65 years, inclusive.
- •2) Expected to survive more than or equal to 2 years from their inclusion in the protocol.
- •3) Able to give informed consent and able to read and/or understand instructions in English, Tamil, Malayalam, Kannada, Hindi, Marathi.
- •4) History of symptoms of RA for greater than 7 years and meets the 2010 ACR/EULAR diagnostic criteria at the time of study entry .
- •5) Rheumatoid Factor positivity or Anti-CCP positivity.
- •6). Active disease as defined by fulfillment of the following criteria at 2 visits that are at the most four weeks apart (i.e., at screening and baseline visits):
- •At least 9 of 68 joints assessed as painful or tender on motion.
- •7) Functional RA classes I, II, or III according to the 1991 ACR classification criteria. Functional RA class IV patients will be permitted if they are not wheelchair or bed bound.
排除标准
- •1. History of an acute inflammatory joint disease as defined by ACR/EULAR criteria other than RA which might interfere with the evaluation of the patientâ??s RA in this study (e.g., SLE, dermatomyositis/polymyositis,reactive arthritis, ankylosing spondylosis, vasculitis).
- •2. Significant symptomatic osteoarthritis.
- •3. Acute major trauma to joints within 1 year of study entry such that the joint is fused or non-functional.
- •4. Previous classic, complete Ayurvedic treatment for RA in the past 6 months, or have used OTC Ayurveda products within 1 month of entry into the study.
- •5. Currently enrolled in another clinical trial or received an investigational drug within 3 months(or 5 halflives, whichever is longer) prior to entry in the study.
- •6. Treatment with intra-articular corticosteroid injections in joint within 4 weeks of study entry.
- •7. Treatment with leflunomide (Arava) within 4 months before intake into study.
- •8. Previous treatment with methotrexate (greater than 4 doses).
- •9. Treatment with biologic or targeted synthetic DMARDS within the periods listed below before their baseline visit.
- •10. Treatment with any immunosuppressive agent (e.g., Azathioprine, Cyclosporine, etc.) within one month of study entry.
- •11. Chronic infections or a previous infection including intestinal ova and parasites requiring antimicrobial therapy within 1 month of study entry.
- •12. Concomitant disorders (e.g., diabetes mellitus, hypertension) which are poorly controlled.
- •13. Cardiac failure (stage III or IV according to the classification of the New York Heart Association, NYHA).
- •14. Uric acid >11mg/dL or well documented episode of gout according to ACR criteria for gout.
- •15. Impaired renal function, as shown by serum creatinine 1.5 times above the ULN of the laboratory.
- •16. Active liver disease OR previous liver disease that has not completely resolved, as shown by serum levels of alkaline phosphatase >2 times lab ULN; SGPT (ALT) >3 times the ULN of the lab; and/or a total bilirubin level less than 2.0 mg/dl 17. Active Hepatitis B or Hepatitis C positive by ELISA; HIV positive per previous screening.
- •18. Active Tuberculosis (TBC). Note. Can be treated and then started on study.
- •19. History of cancer or lymphoproliferative disease in the past 5 years.
- •20. White blood cell count less than 2000/ml, platelet count less than 100, 000/ml, or hemoglobin less than 8 g/L (5.27 mmol/L). If WBC less than 2000/ml but PMN greater than 1000, subject may still be included.
- •21. Any condition that would, in the investigators opinion, compromise the subjects ability to absorb, tolerate, metabolize, or excrete the study medication or could cause unacceptable risk to the patient.
- •22. History of recent, clinically significant drug or alcohol abuse (eg, drug seeking behaviour which intereferes with family or work), in the past six months.
- •23. Mental condition rendering the subjects unable to understand the nature, scope and possible consequence of the study.
- •24. Subject unlikely to comply with protocol (e.g., non-compliance, inability to return for follow-up visits, and likelihood of not completing the study).
- •25. If the patient requires more than 3 g per day acetaminophen or whose NSAID intake is more than the maximum dose allowed in the package insert.
- •26. Pregnant.
- •27. Lactating.
研究者
相似试验
尚未招募
3 期
Study to Compare the Efficacy and Safety of Cilnidipine 10 mg Tablets versus Cilacar® Tablets 10 mg in Patients with Essential HypertensioCTRI/2021/03/031882MACLEODS PHARMACEUTICALS LTD
进行中（未招募）
不适用
This study aims to find out how effective and save Angocin Anti-Infekt N is in treatment of acute uncomplicated cystitis in contrast to standard antibiotics.Treatment of acute uncomplicated cystitisMedDRA version: 14.1Level: PTClassification code 10011781Term: CystitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-022096-54-DERepha GmbH
进行中（未招募）
不适用
A double-blind, double-dummy, prospective, randomized multiple-site study of oral Finafloxacin 300 mg b.i.d. versus oral Ciprofloxacin 250 mg b.i.d. in patients with lower uncomplicated UTI (uUTI) with a treatment duration of 3 days. - FLUTower uncomplicated Urinary Tract InfectionMedDRA version: 9.1Level: LLTClassification code 10046571Term: Urinary tract infectionEUCTR2007-007742-35-DEMerLion Pharmaceuticals GmbH48
撤回
不适用
A prospective randomised double-blind, double-dummy, placebo-controlled crossover study to determine whether Glucagon-like peptide-1 (GLP-1) stimulates or suppresses pancreatic exocrine function in health.Type 2 DiabetesACTRN12614000815662Dr Adam Deane15
已完成
3 期
A prospective, double-blind, double-dummy, randomised controlled trial to compare pain relief from intravenous paracetamol and oral paracetamol in acute pain patients presenting to the Emergency DepartmentPainInjuries and Accidents - Other injuries and accidentsAnaesthesiology - Pain managementACTRN12615000481572The Townsville Hospital and Health Service100